| Triplet therapy, transplantation, and maintenance until progression in myeloma PG Richardson, SJ Jacobus, EA Weller, H Hassoun, S Lonial, NS Raje, ... New England Journal of Medicine 387 (2), 132-147, 2022 | 281 | 2022 |
| Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA G Palladini, E Kastritis, MS Maurer, J Zonder, MC Minnema, ... Blood, The Journal of the American Society of Hematology 136 (1), 71-80, 2020 | 214 | 2020 |
| Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma LJ Costa, S Chhabra, E Medvedova, BR Dholaria, TM Schmidt, KN Godby, ... Journal of Clinical Oncology 40 (25), 2901-2912, 2022 | 184 | 2022 |
| Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR MV Mateos, P Sonneveld, V Hungria, AK Nooka, JA Estell, W Barreto, ... Clinical Lymphoma Myeloma and Leukemia 20 (8), 509-518, 2020 | 147 | 2020 |
| Daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) induction, autologous transplantation and post-transplant, response-adapted, measurable residual disease … LJ Costa, S Chhabra, KN Godby, E Medvedova, RF Cornell, AC Hall, ... Blood 134, 860, 2019 | 94 | 2019 |
| Estradiol levels predict bone mineral density in male collegiate athletes: a pilot study KE Ackerman, GS Skrinar, E Medvedova, M Misra, KK Miller Clinical endocrinology 76 (3), 339-345, 2012 | 63 | 2012 |
| Efficacy of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory myeloma based on prior lines of therapy: updated analysis … MV Mateos, J Estell, W Barreto, P Corradini, CK Min, E Medvedova, M Qi, ... Blood 128 (22), 1150, 2016 | 45 | 2016 |
| Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial LJ Costa, S Chhabra, E Medvedova, BR Dholaria, TM Schmidt, KN Godby, ... The Lancet Haematology 10 (11), e890-e901, 2023 | 42 | 2023 |
| Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) versus bortezomib and dexamethasone (Vd) in first relapse patients (pts) with multiple myeloma (MM … KC Weisel, P Sonneveld, MV Mateos, VTM Hungria, A Spencer, J Estell, ... Blood 134, 3192, 2019 | 41 | 2019 |
| Stem cell mobilization yields with daratumumab-and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and … S Chhabra, N Callander, NL Watts, LJ Costa, B Thapa, JL Kaufman, ... Transplantation and Cellular Therapy 29 (3), 174. e1-174. e10, 2023 | 39 | 2023 |
| Daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): updated efficacy and safety … A Spencer, VTM Hungria, MV Mateos, A Nooka, J Estell, WG Barreto, ... Blood 130, 3145, 2017 | 32 | 2017 |
| Pharmacokinetics and exposure–response analyses of daratumumab in combination therapy regimens for patients with multiple myeloma XS Xu, MA Dimopoulos, P Sonneveld, PJ Ho, A Belch, M Leiba, M Capra, ... Advances in therapy 35, 1859-1872, 2018 | 28 | 2018 |
| Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple … EC Scott, RT Maziarz, SE Spurgeon, E Medvedova, J Gajewski, ... Haematologica 102 (7), e261, 2017 | 24 | 2017 |
| Analysis of transplant-eligible patients (Pts) who received frontline daratumumab (DARA)-Based quadruplet therapy for the treatment of newly diagnosed multiple myeloma (NDMM … N Callander, R Silbermann, JL Kaufman, KN Godby, JP Laubach, ... Blood 140 (Supplement 1), 10144-10147, 2022 | 21 | 2022 |
| Lenalidomide, bortezomib, and dexamethasone (RVd)±autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The … PG Richardson, SJ Jacobus, E Weller, H Hassoun, S Lonial, NS Raje, ... Journal of Clinical Oncology 40 (17_suppl), LBA4-LBA4, 2022 | 13 | 2022 |
| Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) versus bortezomib and dexamethasone (Vd) in first relapse patients: two-year update of CASTOR MV Mateos, P Sonneveld, VTM Hungria, AK Nooka, J Estell, WG Barreto, ... Blood 132, 3270, 2018 | 12 | 2018 |
| Updated interim results from a phase 1 study of HPN217, a half-life extended tri-specific T cell activating construct (TriTAC®) targeting B cell maturation antigen (BCMA) for … AO Abdallah, AJ Cowan, X Leleu, C Touzeau, B Lipe, E Medvedova, ... Blood 140 (Supplement 1), 7284-7285, 2022 | 11 | 2022 |
| Outcomes of MRD-adapted treatment modulation in patients with newly diagnosed multiple myeloma receiving daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) and … LJ Costa, S Chhabra, E Medvedova, TM Schmidt, B Dholaria, KN Godby, ... Blood 140 (Supplement 1), 7275-7277, 2022 | 10 | 2022 |
| Daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd), autologous transplantation and MRD response-adapted consolidation and treatment cessation. Final primary … LJ Costa, S Chhabra, NS Callander, E Medvedova, B Dholaria, ... Blood 138, 481, 2021 | 9 | 2021 |
| Modified hyperCVAD versus bortezomib-hyperCAD in patients with relapsed/refractory multiple myeloma MM Saraceni, E Scott, RT Maziarz, MB Siegel, S Bassale, S Jiing, ... Clinical Lymphoma Myeloma and Leukemia 18 (1), e77-e84, 2018 | 9 | 2018 |
